US$ 27.44
glp-1 receptor agonists effects on cardiovascular risk reduction The of beyond obesity and type 2 diabetes: An anti-atherosclerotic action Discover the Game-Changing Benefits of
Description
Findings: Brand-name manufacturers obtained a median of 19.5 patents per GLP-1 receptor agonist and secured a median of 18.2 years of expected protection
Safer options include medically supervised GLP-1 therapy, nutritional counseling, cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and holistic approaches like mindfulness-based stress reduction

10.1111/dom.12291 138 ZhaoL.ChenY.XiaF.AbudukerimuB.ZhangW.GuoY.et al (2018)
2021, doi: 10.3803/EnM.2020.777
Hypertension 67 , 10561063 (2016)

Future research should also explore tirzepatides effects across different OSAS severities and phenotypes, paving the way for personalized therapeutic strategies